All News

pregnant woman

Reproductive Issues in axSpA: Fertility and Pregnancy

d Sheila Reyes, MD

Axial spondyloarthritis (axSpA) affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their reproductive age. Two interesting abstracts about reproductive issues in axSpA will be presented during the poster sessions on Saturday, November 16, 2024.

Read Article
EULAR19.abstract.jpg (keep)

ACR 2024 - Featured Industry Presentations

d Jack Cush, MD

ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
Characteristics of difficult-to-treat AS accdg to a retrospective study by @DaoudAnsaam @mmagrey1 et al ⬆️ BMI + comorbidities: HTN, CKD, depression + EAMs: IBD, Pso, iridocyclitis + HLA-B27 Interesting real world data. @RheumNow #ACR24 abs573 https://t.co/GlE4tFpsSz

Links:

sheila RHEUMarampa ( View Tweet)
Data from the study by Dr. Aguilar et al showed that high dose NSAID use was not assoc'd with incident HTN in their cohort of early axSpA patients. Shows important role of NSAIDs in #axSpA but still should be used judiciously @RheumNow #ACR24 abs540 @rheum_cat @rheumarhyme https://t.co/LK5yFZynu4

Links:

sheila RHEUMarampa ( View Tweet)
Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. Abstr#0572 @RheumNow #ACR24 https://t.co/1tQUhsbqUu

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

#0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch ➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TNFi cyclers @ 6 mo ➡️PsA: Switchers had improved arthritis/psoriasis(-5.0, p=0.02) ➡️axSpA: Switchers had improved fatigue(-9.4, p=0.01) #ACR24 @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

In the SPACE cohort, patients with chronic back pain suspected of axial spondyloarthritis often receive a diagnosis within 35 months from symptom onset. Key determinants for early diagnosis include HLA-B27 positivity and sacroiliitis on imaging. Early diagnosis can be a game… https://t.co/RrcrtRoMfL

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Is biologic response different in men vs women with axSpA? A Meta-analysis of 11 studies including 11,199 axSpA pts evaluated sex-related response to bDMARDs -Male pts more likely to achieve BASDAI 50 and ASDAS low disease activity responses compared to females. #Abst0599… https://t.co/FopBLS4bF6 https://t.co/PpoZB9HwZN

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Is biologic response different in men vs women with axSpA? A Meta-analysis of 11 studies including 11,199 axSpA pts evaluated sex-related response to bDMARDs -Male pts more likely to achieve BASDAI 50 and ASDAS low disease activity responses compared to females. #Abst0599… https://t.co/FopBLS4bF6 https://t.co/PpoZB9HwZN

Links:

Adela Castro AdelaCastro222 ( View Tweet)
The METEOR study reveals distinct clinical features in spondyloarthritis (SpA) patients with vs. without IBD. Key features of those with IBD: - Lower male prevalence - Higher uveitis rates - Lower psoriasis rates - More structural damage in SI joints Mirroring gut… https://t.co/EyBZQ91DDn

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis. Another innovation that may help with the rapid… https://t.co/qSwryK22uj

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

Links:

Adela Castro AdelaCastro222 ( View Tweet)

A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including: - Higher BMI - Increased comorbidities - Presence of EAMs - HLA-B27 positivity is linked to higher odds of being D2T, highlighting potential genetic… https://t.co/XcShdxSwhm

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA. Makes sense in a way since longer dse duration may play a role. 🔶️THM - screen SpA pts for IBD; ask for GI symptoms @RheumNow #ACR24 abs554 https://t.co/Q6jeDUFa8Z

Links:

sheila RHEUMarampa ( View Tweet)
TNFi cycling vs. switching to IL-17Ai? Dr @AlexisOgdie et al from CorEvitas registry: PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF) Not stat significant but offers alternative Tx options @RheumNow #ACR24 abs585 https://t.co/8m347BRM75

Links:

sheila RHEUMarampa ( View Tweet)
Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX

Links:

Patricia Harkins DrTrishHarkins ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

Dr. Quotes (11.8.2024) Dr. Jack Cush reviews the news and journal reports from this past week from https://t.co/V10S4oWdi3. https://t.co/NEXFg3Mp5G https://t.co/tUkGSgm6O7

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×